Survodutide

Two programs, one molecule: survodutide (BI 456906) runs in parallel in obesity research (SYNCHRONIZE) and in liver research (LIVERAGE). It was originally developed at Zealand Pharma, and Boehringer Ingelheim carries the further investigation.

The mechanism in brief:

• GLP-1 receptor: the familiar incretin pathway.
• Glucagon receptor: linked in research models to higher energy expenditure, increased lipolysis and better liver readouts.
• Distinction: tirzepatide pairs GLP-1 with GIP, survodutide pairs it with glucagon instead.

State of the data:

• Clinical program running since 2020.
• SYNCHRONIZE (phase 3): first results in April 2026, 16.6 percent less body weight after 76 weeks, with the loss coming mostly from fat tissue.
• LIVERAGE: research on MASH and liver fibrosis, granted Breakthrough Therapy designation by the FDA.
• Pharmacokinetics: half-life of about five to six days, one subcutaneous administration per week in the protocols.

Because the glucagon pathway runs as the second component, survodutide is of particular interest for questions where lipid metabolism or hepatic markers take center stage. Within the GLP-1 family, few molecules share this profile. Below you find the phase 2 dose-finding trial, the comparison with semaglutide in type 2 diabetes and the design paper of the cardiovascular outcomes trial.

According to the studies, survodutide is well tolerated overall; as a GLP-1/glucagon dual agonist it shows the picture typical of the class, centered on the gut and dose-dependent in the phase 2 data.

• Stomach and bowel: nausea, vomiting, diarrhea and constipation occur most often, mainly at the start and with rapid dose increases; slower escalation lowered the rate.
• Fluids: a dampened appetite can reduce food and fluid intake, and the literature cites a raised risk of dehydration.
• Heart rate: mild increases are documented for the glucagon component.
• Muscle and injection site: part of the weight loss is muscle mass, and the injection site can show mild irritation.
• Time horizon: the clinical program is still running, and robust data on very long use are missing.

This summary is no substitute for medical advice.

• Glucagon and GLP-1 receptor dual agonist survodutide for obesity: Phase 2 trial - the dose-finding trial in obesity research.
• Dose-response effects on HbA1c and bodyweight reduction of survodutide vs semaglutide - survodutide against semaglutide in a type 2 diabetes population.
• Rationale and Design of the SYNCHRONIZE Cardiovascular Outcomes Trial - lays out structure and rationale of the outcomes trial with 4935 planned adults (BMI 27 or higher, elevated cardiovascular risk), primary endpoint being time to the first major adverse cardiovascular event; the paper carries no results.